- Home
- ORBS vs NGNE Comparison
ORBS vs NGNE Comparison
Compare ORBS & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORBS | NGNE |
|---|---|---|
| Founded | 1966 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.9M | 327.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORBS | NGNE |
|---|---|---|
| Price | $1.36 | $17.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $40.14 |
| AVG Volume (30 Days) | ★ 3.9M | 129.3K |
| Earning Date | 11-14-2025 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,116,096.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $0.98 | $6.88 |
| 52 Week High | $83.12 | $37.27 |
Technical Indicators
Market Signals| Indicator | ORBS | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 37.23 |
| Support Level | $1.17 | $15.93 |
| Resistance Level | $1.63 | $18.95 |
| Average True Range (ATR) | 0.13 | 1.35 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 8.70 | 8.20 |
Price Performance
Historical ComparisonAbout ORBS Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.